Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT00675493

BIASP-3567

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in Romania.

Enrollment: 942 patients

Sex: All

Ages: 10 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 1 and type 2 diabetics who are treated with human premix insulin (the selection of the subjects will be at the discretion of the individual physician).

Exclusion criteria

• Subjects currently being treated with biphasic insulin aspart 30
• Subjects who were previously enrolled in this study
• Subjects with a hypersensitivity to biphasic insulin aspart 30 or to any of the excipients
• Women who are pregnant or have the intention of becoming pregnant within next 6 months
• Children below 10 years of age

Trial design

942 participants in 1 patient group

A

Treatment:

Drug: biphasic insulin aspart 30